Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endomyocardial Biopsy in Suspected Immune Checkpoint Inhibitor-Myocarditis: Histologic Spectrum and Correlations With Clinical and Cardiac Magnetic Resonance Features.

Journal of the American Heart Association·2026
Same author

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer.

NPJ breast cancer·2026
Same author

Breast cryoablation for small, low-risk breast cancers: Current evidence, practical integration, and future directions.

Diagnostic and interventional imaging·2026
Same author

E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer.

Nature communications·2026
Same author

Circulating Tumor DNA Monitoring in Patients with Uveal Melanoma Using Mutation-Agnostic Multiplex Drop-Off ddPCR Assays.

Analytical chemistry·2026
Same author

Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial.

NPJ breast cancer·2026

Related Experiment Video

Updated: Mar 7, 2026

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
07:47

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

4.7K

Circulating tumor cells: clinical validity and utility.

Luc Cabel1,2, Charlotte Proudhon3, Hugo Gortais4

  • 1Department of Medical Oncology, Institut Curie, PSL Research University, 26 rue d'Ulm, 75005, Paris, France. luc.cabel@curie.fr.

International Journal of Clinical Oncology
|February 27, 2017
PubMed
Summary
This summary is machine-generated.

Circulating tumor cells (CTCs) show promise as biomarkers for cancer diagnosis and prognosis. While not yet standard, their clinical validity is high, particularly in breast, lung, colorectal, and prostate cancers, guiding potential treatment strategies.

Keywords:
BiomarkersCirculating tumor cellsClinical trialsClinical utilityClinical validity

More Related Videos

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model
05:22

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Published on: October 9, 2015

12.7K
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.3K

Related Experiment Videos

Last Updated: Mar 7, 2026

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research
07:47

Circulating Tumor Cell Lines: an Innovative Tool for Fundamental and Translational Research

Published on: December 25, 2021

4.7K
Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model
05:22

Isolation and Propagation of Circulating Tumor Cells from a Mouse Cancer Model

Published on: October 9, 2015

12.7K
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

16.3K

Area of Science:

  • Oncology
  • Biomarker Research
  • Cancer Diagnostics

Background:

  • Circulating tumor cells (CTCs) are rare cells shed from tumors into the bloodstream.
  • CTCs are investigated as diagnostic, prognostic, and predictive biomarkers across various cancers.
  • Despite high clinical validity, CTCs are not yet standard in clinical practice.

Purpose of the Study:

  • To review the clinical validity and utility of CTCs in metastatic and non-metastatic cancer.
  • To focus on the application of CTCs in breast, lung, colorectal, and prostate cancers.
  • To discuss treatment strategies informed by CTCs as liquid biopsies, counts, variations, and biomarker expression.

Main Methods:

  • Literature review of studies on CTCs in oncology.
  • Analysis of clinical validity and utility data for CTCs.
  • Summary of ongoing and published Phase II and III trials involving CTCs.

Main Results:

  • CTCs demonstrate significant clinical validity, especially in breast, lung, colorectal, and prostate cancers.
  • Clinical utility is being explored through treatment decisions based on CTC liquid biopsy, counts, and biomarker expression.
  • Numerous clinical trials are investigating the impact of CTCs on patient outcomes.

Conclusions:

  • CTCs hold substantial potential as valuable biomarkers in oncology.
  • Further research and clinical trials are crucial to integrate CTCs into routine cancer care.
  • Understanding CTCs can lead to personalized treatment approaches and improved patient management.